Interestingly, high LAYN and HAVCR2 expression levels were found to be associated with anti-PD1 therapy when administered in melanoma and NSCLC-HNSC-melanoma in other studies, respectively (Figure S12C) [28,29]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.